Navigation Links
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
Date:5/22/2008

stents placed in the first year, compared to 15 percent of patients who received bare-metal stents. Few patients in either arm required bypass surgery in the first year following stent placement, but those who received bare-metal stents were twice as likely to need the procedure, leading to an additional cost savings of $714 per patient treated with drug-coated stents. Overall, researchers found that patients with drug-eluting stents each saved an average of $1,350 worth of follow-up care during the year, which projects a total savings of approximately $100 million dollars among the 72,000 drug-eluting stent patients studied.

The researchers note that future studies should focus on how drug therapies including clopidogrel and cholesterol-reducing statin drugs may play a role in outcomes and costs for both types of stent patients. Since recent evidence shows that clopidogrel therapy -- aimed at reducing the risk of blood clots following stent placement -- is an essential step for reducing late drug-eluting stent complications or failure, Groeneveld theorizes that clinical outcomes for drug-eluting stent patients might be boosted even further when patients follow an appropriate long-term drug regimen.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
... U.S. is getting metamorphosed into luxurious buil...ipments which may offer good patient hospitality b...g to non-accessible of poor patients to these luxu...s changing from a semi-private health system to co...
...licy to Briton citizen could increase advertising ...y is aimed at // reducing the waiting time of th...eople can make their own choice of treatment at an... their comfortable location and choice. Health Sec...
...hat is mainly present in pain relievers. Recently ...ing the // clinicians complaining about over dosa...re of the liver but about 50% of these cases are u...yl, Contac, Excedrin, Robitussin, Nyquil and Sinut...
...ty of California have now established a very stron...ure, or end-stage renal disease. So if you are thi...away, as there is no time to lose. // "There are...ure, but it hasn't been appreciated much that kidn...
Other Medicine News:Health News:Painkillers Lead To Liver Failure 2
(Date:7/24/2008)... New JIT Enrollment Program Speeds Oncology... Pharmatech, Inc., a Research Management,Organizat...ceutical,companies to provide research and site ma...the Just-in-Time (JIT) enrollment strategy. The ne...: follicular Non-Hodgkin,s,Lymphoma, Metastatic Br...
(Date:7/24/2008)... NEW YORK, July 24 /- Mac...y announced results of a Phase 2 clinical trial,in...multi-center,open-label efficacy and safety study...treatment of onychomycosis (nail fungus). The comp...complete cure" defined as,negative mycology (negat...
(Date:7/23/2008)... - Nexavar is First Approved Systemic Therapy to... Calif., July 23 /-,Bayer H..., Inc. (Nasdaq:,ONXX) today announced that The New...a Phase 3 trial demonstrating that Nexavar(R) (sor...th by 31 percent in patients with,unresectable hep...
(Date:7/23/2008)... SEATTLE, July 23 /- Sound Pharmace...g Application with the FDA for the clinical,testin...prevention of,chemotherapy induced hearing loss or... SPI-3005, will be tested in advanced stage lung c...platinum based chemotherapy.,This marks the second...
Breaking Medicine Technology:Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Rocky water source 3607 1Rocky water source 3607 2Sex offenders register provides limited protection for children 21576 1Sex offenders register provides limited protection for children 21576 2Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 1Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 2Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 1Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 2
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles.
Sabre 180 is a powerful niche generator.
Sabre 180 is a powerful niche generator.
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
Medicine Products: